Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin-Reference-Cited by-同舟云学术

Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin

Published:2019-09 Issue: Volume:98 Page:104-111
ISSN:0026-0495
Container-title:Metabolism
language:en
Short-container-title:Metabolism

Author:

Alexopoulos Anastasia-Stefania,Buse John B.

Funder

National Institutes of Health

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Reference82 articles.

1. Time to insulin treatment and factors associated with insulin prescription in Swedish patients with type 2 diabetes;Ringborg;Diabetes Metab,2010

2. Time to and factors associated with insulin initiation in patients with type 2 diabetes mellitus;Machado-Alba;Diabetes Res Clin Pract,2015

3. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD);Davies;Diabetes Care,2018

4. Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings;Guerci;Diabetes Metab,2019

5. Efficacy and acceptability of glycemic control of glucagon-like peptide-1 receptor agonists among type 2 diabetes: a systematic review and network meta-analysis;Li;PLoS One,2016

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gut microbiota associated with appetite suppression in high-temperature and high-humidity environments;eBioMedicine;2024-01

2. Comparison of GLP-1 receptor agonists and other Glucose-Lowering agents on cardiovascular outcomes in individuals with type 2 diabetes and Obesity: A Spanish Real-World Population-Based study;Diabetes Research and Clinical Practice;2024-01

3. Treatment Approaches and Challenges;Nanoscience Applications in Diabetes Treatment;2023-12-17

4. Efficacy and Safety of a Biosimilar Liraglutide (Melitide®) Versus the Reference Liraglutide (Victoza®) in People with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Noninferiority Clinical Trial;Diabetes Therapy;2023-09-14

5. Real-World Evaluation of GLP-1 Receptor Agonist Therapy Persistence, Adherence and Therapeutic Inertia Among Obese Adults with Type 2 Diabetes;Diabetes Therapy;2023-02-27